ArticleProstate international2021
Rebiopsy rate after transperineal or transrectal prostate biopsy.
Article in Prostate international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2024Pooled it
- Ultrasound-Guided Transperineal Versus Transrectal Prostate Aspiration Biopsy in Diagnosing Prostate Cancer: An Observational Comparison Study.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2026Observational
- Superior cancer detection with transperineal biopsy in patients with an elevated prostate-specific antigen level and a PI-RADS score of 3-4: A retrospective cohort study.Oncology letters · 2026Article
- Clinical significance of MRI PI-RADS 3 lesions upgraded by dynamic contrast enhancement: the "PI-RADS 3 + 1" subgroup.International urology and nephrology · 2026Article
- AI-based detection of MRI-invisible prostate cancer with nnU-Net.The Canadian journal of urology · 2025Article
- Review
- Prostate cancer diagnosis and management: current practices in Africa a consultant-based survey.Frontiers in urology · 2025Article
- High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review.Journal of personalized medicine · 2024Review
- Detection of anterior prostate cancer using a magnetic resonance imaging-transrectal ultrasound fusion biopsy in cases with initial biopsy and history of systematic biopsies.Prostate international · 2023Article
- Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility.Diagnostics (Basel, Switzerland) · 2023Review
- Bilateral Seminal Vesicle Invasion Is Not Associated with Worse Outcomes in Locally Advanced Prostate Carcinoma.Medicina (Kaunas, Lithuania) · 2022Observational
- Antibiotic prophylaxis in patients who had undergone to prostate biopsy in between the EMA warning era: effects of fluoroquinolones in diabetic and non-diabetic patients. Results of an observational cohort study.World journal of urology · 2022Observational
- Is antibiotic prophylaxis still mandatory for transperineal prostate biopsy? Results of a comparative study.Prostate international · 2022Article
- Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: A retrospective study.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, transperineal biopsies gained popularity for prostate cancer diagnosis; lower infective complications and improved sampling of the prostate are the main advantages of this technique. One question that remains unclear is whether an initial transperineal biopsy confers a lower risk for rebiopsy compared with the transrectal approach.
methodsSix hundred seventy-one men were prospectively followed after an initial negative prostate biopsy for a median period of 49.50 (IQR: 37.62-61.17) months. Rebiopsy rate was analyzed attending to first biopsy approach (transrectal versus transperineal systematic) and clinical variables.
resultsDiagnostic rate was similar for transrectal and transperineal systematic biopsies. Targeted biopsies outperformed any systematic approach, and transperineal targeted in particular was superior to transrectal targeted. Rebiopsy rates were 15.4% and 5.26% for the transrectal and transperineal systematic groups, respectively. Prostate-specific antigen density and type of first biopsy were identified as rebiopsy predictors.
conclusionMen undergoing transperineal systematic biopsies had a three times lower rate of rebiopsy over the study period compared with the traditional transrectal approach. This advantage could be added to the already described potential benefits of transperineal biopsies. Targeted biopsies had lower rebiopsy rate over the study period. Further innovations that decreased the cost of transperineal biopsies could favor this approach in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.